Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Sugimoto, Shinichi ^a   Katano, Kuniyuki ^b   Kanazawa, Akiyoshi ^a,c   Yoshimura, Hiroshi ^d,e   Kidani, Akihiko ^c   Takeda, Hiroshi ^a   Makino, Masato ^b,f   Ozaki, Nobuhiro ^a   Tanaka, Tsuneo ^d   Ikeguchi, Masahide ^b  

^a SHIMANE PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c OSAKA RED CROSS HOSPITAL   (Japan)

^d SHIMANE UNIVERSITY   (Japan)

^e Nakagawa Hospital   (Japan)

^f Nojima Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 69449100159     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-109     Document Type: Article

References (26)

1. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. RM Goldgerg DJ Sargent RF Morton CS Fuchs RK Ramanathan SK Williamson BP Findlay HC Pitot SR Alberts, J Clin Oncol 2004 22 23 30
2. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. C Tournigand T André E Achille G Lledo M Flesh D Mery-Mignard E Quinaux M Buyse G Ganem B Landi P Colin C Louvet A de Gramont, J Clin Oncol 2004 22 229 37
3. Japanese Society for Cancer of the Colon and Rectum, Guidelines for Management of Colon Cancer (for Physicians, Version 2005) Tokyo: Kanehara & Co., Ltd 2005
4. New guidelines to evaluate the response to treatment in solid tumors. P Therasse SG Arbuck E Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther, J Natl Cancer Inst 2000 92 205 216 (Pubitemid 30099779)
5. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. The advanced colorectal meta-analysis project, J Clin Oncol 1992 10 893 903
6. Chemotherapy of large bowel cancer. HL Davis, Cancer 1982 50 2638 2646
7. A phase III trial of 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer. MJ O'Connell, Cancer 1989 63 1026 10302465076
8. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim Results of a phase III trial. ML Rothenberg AM Oza RH Bigelow JD Berlin JL Marshall RK Ramanathan LL Hart S Gupta CA Garay BG Burger N Le Bail DG Haller, J Clin Oncol 2003 21 2059 2069
9. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. A de Gramont A Figer M Seymour M Homerin HJ Cassidy C Boni H Cortes-Funes A Cervantes G Freyer D Papamichael N Le Bail D Hendler F de Braud C Wilson F Morvan A Bonetti, J Clin Oncol 2000 18 2938 2947
10. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. S Giacchetti B Perpoint R Zidani N Le Bail R Faggiuolo C Focan P Chollet JF Llory Y Letourneau B Coudert F Bertheaut-Cvitkovic D Larregain-Fournier A Le Rol S Walter R Adam JL Misset F Lévi, J Clin Oncol 2000 18 136 147
11. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 6). F Maindrault-Goebel C Louvet T André E Carola JP Lotz JL Molitor ML Garcia V Gilles-Amar V Izrael M Krulik A de Gramont, Eur J Cancer 1999 35 1338 1342
12. Modified FOLFOX6 treatment in patients with unresectable or recurrent colorectal cancer. K Ishibashi J Sobajima M Yokoyama T Mitsuhashi T Miyazaki H Nakada T Gonda J Nakano M Sano H Ishida, Japanese Journal of Cancer Clinics 2007 53 57 63
13. Drug therapy: drug disposition in old age. DJ Greenblatt EM Sellers RI Shader, N Engl J Med 1982 306 1081 1088
14. Management of drug therapy in the elderly. SC Montamat BJ Cusack RE Vestal, N Engl J Med 1989 321 303 309
15. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. H Hurwitz L fehrenbacher W Novontny T Carwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross, N Engl J Med 2006 350 2335 2342
16. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. FF Kabbinavar HI Hurwitz J Yi S Sarkar O Rosen, J Clin oncol 2009 27 199 205
17. Phase II, Randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland, J Clin oncol 2003 21 60 65
18. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. FF Kabbinavar J Schulz M McCled T Patel JT Hamm R Hecht R Mass B Perrou B Nelson WF Novotny, J Clin oncol 2005 23 3697 3705
19. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. A Grothey D Sargent RM Goldberg HJ Schmoll, J Clin oncol 2004 22 1209 1214
20. Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patient With Colorectal Cancer. RM Goldberg I Tabah-Fisch H Bleiberg A de Gramont C Tournigand T Andre ML Rothenberg E Green DJ Sargent, J Clin Oncol 2006 24 4085 4091
21. Efficacy of Intravenous Infusion of Fluorouracil Compared with Bolus Administration in Advanced Colorectal cancer. Meta-analysis Group In Cancer, J Clin Oncol 1998 16 301 308
22. Toxicity of Fluorouracil in patients With Advanced Colorectal cancer: Effect of Administration Schedule and Prognostic Factors. Meta-analysis Group in Cancer, J Clin Oncol 1998 16 3537 3541
23. The Value of Oxaliplatin in combination with continuous infusion Bolus 5-Fluorouracil and Levo-Folinic Acid in Metastatic Colorectal Cancer Progressing After 5FU-Based Chemotherapy: A GISCAD (Italian Group For The Study Of Digestive Tract) Cancer Phase II Trial. S Mosconi S Csscinu A Zaniboni, Tumori 2000 86 465 469
24. Oxaliplatin-safety profile: Neurotoxicity. A Grothey, Oncol 2003 30 5 13
25. OPTIMOX 1: a randomized study of FOLFOX4 or FOLFOX7 with Oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. C Tournigrand A Cervantes A Figer G Lledo M Flesch M Buyse L Mineuer E Calola PL Etienne F Rivera I Chirivella N Perez-Staub C Louvet T André I Taban-Fisch A de Gramont, J Clin Oncol 2006 24 394 400
26. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX 1 study. A Figer N Perez-Staub E Carola C Tournigrand G Lledo M Flesch R Barcelo A Cervantes T André P Colin C Louvet A de Gramont, Cancer 2007 110 2666 2671